Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs. Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or complementary with the use of inhaled corticos...
Montelukast is indicated for:
...
The Royal Children's Hospital, Parkville, Victoria, Australia
Department of Radiology, Guangzhou, Guangdong, China
GSK Investigational Site, Bellville, South Africa
Genuine Research Center GRC, Cairo, Egypt
Genuine Research Center GRC, Cairo, Egypt
Research Site, Madison, Wisconsin, United States
Indiana University School of Medicine, Indianapolis, Indiana, United States
Kewu Huang, China, Beijing, China
Hammersmith Medicines Research Ltd, London, United Kingdom
Beijing Chaoyang Hospital affiliated to Capital Medical University, Beijing, Beijing, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.